doi: 10.1016/S0140-6736(21)01324-6 Summary Keywords glucagon, GLP-1, obesity, co-agonist, weight loss Citation Hope DCD, Vincent ML and Tan TMM (2021) Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
Even though semaglutide weight loss has FDA approval, it has some side effects that patients need to know
While further research has to be conducted to solidify the link between cognition and IGF-1, IGF-1 has been proven to act at AMPARs to initiate changes in synaptic structure and protein expression
While hydroxychloroquine is not a typical 'NSAID' like naproxen, combining them can sometimes increase the likelihood of gastrointestinal side effects or affect kidney function, especially during long-term use
they shed an average of 15% of their total body weight